Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma
TLDR
The authors examined the time trends and patterns of use for androgen deprivation in the form of gonadotropin‐releasing hormone (GnRH) agonists or orchiectomy, in population‐based tumor registries.Abstract:
BACKGROUND
The role of androgen deprivation therapy in prostate carcinoma is controversial in earlier stages of disease. The authors examined the time trends and patterns of use for androgen deprivation in the form of gonadotropin-releasing hormone (GnRH) agonists or orchiectomy, in population-based tumor registries.
METHODS
Data were obtained from the linked Surveillance, Epidemiology and End Results-Medicare database. A total of 100,274 men with prostate carcinoma diagnosed from 1991 through 1999 were selected. The main outcome was the proportion of men who received ≥ 1 dose of a GnRH agonist in the first 6 months of diagnosis. This was plotted by year and stratified for age, grade, stage as well as primary versus adjuvant usage. Multiple logistic regression was used to examine predictors of GnRH agonist use in the subset of patients with localized cancer.
RESULTS
There was a consistent increase in GnRH agonist use by year for all ages, stages, and grades. Even in men ≥ 80 years with localized stage and low to moderate grade tumors, primary GnRH agonist use increased over the study period, from 3.7% in 1991 to 30.9% in 1999 (P < 0.001). The multivariable analysis showed that significant variability in GnRH agonist use existed among SEER geographic regions.
CONCLUSIONS
The use of GnRH agonists for prostate carcinoma increased dramatically during the 1990s. This increase occurred across all stages and histologic grades of prostate carcinoma, and was greatest in patients ≥ 80 years. Cancer 2005. © 2005 American Cancer Society.read more
Citations
More filters
Journal ArticleDOI
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W. Kantoff,Celestia S. Higano,N. Shore,E. Roy Berger,Eric J. Small,David F. Penson,Charles H. Redfern,Anna C. Ferrari,Robert Dreicer,Robert B. Sims,Yi Xu,Mark W. Frohlich,Paul F. Schellhammer +12 more
TL;DR: The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer and immune responses to the immunizing antigen were observed in patients who received sipuleUcel- T.
Journal ArticleDOI
Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer
TL;DR: GnRH agonist treatment for men with locoregional prostate cancer may be associated with an increased risk of incident diabetes and cardiovascular disease and the benefits of GnRH agonists should be weighed against these potential risks.
Guidelines on Prostate Cancer
Axel Heidenreich,Joaquim Bellmunt,Michel Bolla,Steven Joniau,Vsevolod Matveev,N. Mottet,Thomas Wiegel,Filiberto Zattoni +7 more
TL;DR: The introduction of an effective blood test, prostate specific antigen (PSA), has made it possible to diagnose more and more men in an earlier stage where they can be offered potentially curative treatments, and this is the subject of the EAU guidelines on prostate cancer.
Journal ArticleDOI
Combined Resistance and Aerobic Exercise Program Reverses Muscle Loss in Men Undergoing Androgen Suppression Therapy for Prostate Cancer Without Bone Metastases: A Randomized Controlled Trial
TL;DR: A relatively brief exposure to exercise significantly improved muscle mass, strength, physical function, and balance in hypogonadal men compared with normal care and could be recommended for patients undergoing AST as an effective countermeasure to these common treatment-related adverse effects.
Journal ArticleDOI
Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer
TL;DR: Androgen deprivation therapy with GnRH agonists was associated with an increased risk of diabetes and cardiovascular disease and oral antiandrogen monotherapy was not associated with any outcome studied.
References
More filters
Journal ArticleDOI
Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: a national survey of urologist beliefs and practices
TL;DR: Many urologists maintain an inclination to prescribe androgen deprivation for a rising or elevated PSA despite the absence of information about the benefit of this approach and their own conflicting beliefs.
Journal ArticleDOI
The cost value of medical versus surgical hormonal therapy for metastatic prostate cancer.
TL;DR: It is indicated that medical hormonal therapy costs significantly more than bilateral orchiectomy but creates positive value for men with prostate cancer by enabling them to avoid orchi surgery.
Journal ArticleDOI
United States radiation oncologists' and urologists' opinions about screening and treatment of prostate cancer vary by region.
Mary McNaughton Collins,Michael J. Barry,Anthony L. Zietman,Peter C. Albertsen,James A. Talcott,Elizabeth Walker Corkery,Diana B. Elliott,Floyd J. Fowler +7 more
TL;DR: Florida radiation oncologists and urologists reported beliefs and practices that differed from their colleagues in other regions of the United States, whether the distinctive style of prostate cancer diagnosis and treatment in Florida results in improved outcomes has yet to be proved.